Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from VRTX

IBD Stock Of The Day: Vertex Briefly Breaks Out On Bullish Diabetes Data

Recent IBD Stock Of The Day Vertex Pharmaceuticals briefly broke out Wednesday on promising test results in diabetes.

Investors Business Daily

$100 Invested In This Stock 10 Years Ago Would Be Worth $500 Today

Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 10 years by 4.83% on an annualized basis producing an average annual return of 16.83%. Currently, Vertex Pharmaceuticals has a market capitalization of $68.84 billion.

Benzinga

IBD Tech Leader Vertex Snags Upgrade As Non-Cystic Fibrosis Drugs Crystallize

Vertex Pharmaceuticals got an upgrade Wednesday on its burgeoning non-cystic fibrosis pipeline — as VRTX stock inched higher.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

Vertex Pharmaceuticals Receives Composite Rating Upgrade

The IBD SmartSelect Composite Rating for Vertex Pharmaceuticals increased from 94 to 96 Tuesday.

Investors Business Daily

2 Recession Stocks to Buy Right Now

Multi-decade-high inflation and aggressive Fed rate increases might push the economy into a recession. So, investors looking to mitigate a market downturn should invest in Dollar Tree (DLTR) and Vertex Pharmaceuticals (VRTX), as they could deliver stable returns because their businesses enjoy a near-inelastic demand.

StockNews.com

1 Biotech Stock to Buy and 1 to Sell

Increasing investments in R&D to develop new therapies, rising cases of chronic diseases, and an aging population should drive the biotech market’s growth. Therefore, we think it could be wise to invest in the shares of fundamentally sound biotech company Vertex Pharmaceuticals (VRTX). Conversely, we think the shares of Galmed…

StockNews.com

Dow Jones Futures Fall After Stocks Plunge, Treasury Yields Soar In Delayed Fed Reaction

Treasury yields surged in a delayed reaction to the Fed meeting. Stocks dived, wiping out Wednesday's market rally.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

Why Vertex Pharma's Pipeline Has Never Been More Important

Vertex will need to lean on its pipeline to prop VRTX stock, an analyst said Thursday after the company delivered a mixed report.

Investors Business Daily

Analyst Ratings for Vertex Pharmaceuticals

Over the past 3 months, 4 analysts have published their opinion on Vertex Pharmaceuticals (NASDAQ:VRTX) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Benzinga

$1000 Invested In Vertex Pharmaceuticals 5 Years Ago Would Be Worth This Much

Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 5 years by 6.39% on an annualized basis producing an average annual return of 17.51%. Currently, Vertex Pharmaceuticals has a market capitalization of $65.74 billion.

Benzinga

Dow Jones Slumps 200 Points, But Warren Buffett Stock Chevron Bucks The Trend; 2 Hot Steel Stocks Test Key Level

The Dow Jones was near session lows in afternoon trading Monday, but Buffett stock Chevron was a bright spot, along with Honeywell.

Investors Business Daily

Vertex Pharma's Stem Cell Derived Diabetes Treatment Trial Put On Hold

The FDA has instituted a clinical hold on Vertex Pharmaceuticals Incorporated's (NASDAQ:VRTX) VX-880 Phase 1/2 study due to a determination that there is insufficient information to support dose escalation with the product. VX-880 is an investigational stem cell-derived, fully differentiated pancreatic islet cell replacement therapy for type 1 diabetes (T1D). Three patients have been…

Benzinga

4 Biotech Stocks to Add to Your Watchlist

The surging demand for viable drugs and vaccines, advanced therapies, and increasing investments in research and development make the biotech industry’s prospects bright. Thus, it could be wise to invest in fundamentally sound biotech stocks Amgen (AMGN), Vertex Pharmaceuticals (VRTX), BioNTech (BNTX), and Corcept Therapeutics (CORT).

StockNews.com

5 Resilient Stocks to Buy for a Market Downturn

Yesterday, the broad market indices closed in negative territory on interest-rate-increase concerns. Goldman Sachs has predicted that the S&P might tumble to 3,600 this year if recessionary pressure persists. Non-cyclical stocks usually perform well during economic downturns. So, we believe Cardinal Health (CAH), Brookfield Infrastructure Corp. (BIPC), Smith & Nephew…

StockNews.com

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

If You Invested $1000 In Vertex Pharmaceuticals 15 Years Ago, Here's How Much You Would Have Today

Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 15 years by 8.29% on an annualized basis producing an average annual return of 15.84%. Currently, Vertex Pharmaceuticals has a market capitalization of $72.91 billion.

Benzinga

$100 Invested In Vertex Pharmaceuticals 15 Years Ago Would Be Worth This Much

Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 15 years by 7.35% on an annualized basis producing an average annual return of 15.26%. Currently, Vertex Pharmaceuticals has a market capitalization of $67.63 billion.

Benzinga

Vertex Touts Positive Data From Mid-Stage Study Of Its Non-Opioid Pain Drug

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) released positive results from two Phase 2 post-operative trials for its non-opioid program, VX-548. One trial looked at patients who had just received a bunionectomy (Correcting the deformity of toes & foot), the other in patients who received abdominoplasty (tummy tuck). Vertex said that within 48 hours of surgery,…

Investors Business Daily

Vertex Continues Its Meteoric Run After Its Opioid Alternative Scores In A Key Test

Vertex announced promising test results for its opioid alternative on Thursday, sending VRTX stock deeper into breakout territory.

Get all your
news in one place.

100’s of premium titles.
One news app.

StockNews.com

3 Red-Hot Large-Cap Stocks Outpacing the S&P 500

Large-cap stocks are generally known to provide better safety to investors during periods of volatility. Therefore, we think Bristol-Myers Squibb (BMY), Vertex (VRTX), and Molina Healthcare (MOH), which have been outpacing the S&P 500, might be good investments now.

Benzinga

$1000 Invested In Vertex Pharmaceuticals 5 Years Ago Would Be Worth This Much

Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 5 years by 9.35% on an annualized basis.

StockNews.com

5 Top-Rated Recession Resistant Stocks to Buy Immediately

Growing Western sanctions on Russia could cause further industrial supply disruptions. In addition, crude oil prices have been skyrocketing. Therefore, many analysts are forecasting the emergence of a recessionary environment. Given this backdrop, we think it could be wise to bet on defensive stocks Vertex Pharmaceuticals (VRTX), Ambev (ABEV), AmerisourceBergen…

Investors Business Daily

As Vertex Stock Looks More Bullish, This Trade Limits Risk

The ideal scenario for this Vertex stock option trade is a rise up to 260 around April 14 with stable or rising implied volatility.

StockNews.com

4 Outperforming Growth Stocks to Buy in March

The United States economy is growing strongly, outperforming other developed economies. Furthermore, analysts believe the country is well-positioned to weather economic challenges created by the Russia-Ukraine war. So, we think that growth stocks Vertex Pharmaceuticals (VRTX), Fair Isaac (FICO), Ralph Lauren (RL), and Exelixis (EXEL), which have outpaced the broader…

Benzinga

This Biopharmaceutical Company Has A Better 1-Year Return Than Tesla, Apple, Starbucks, Nvidia And Microsoft

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) creates new possibilities via medicine to cure diseases and improve people's lives, and over the past year, marked gains in investors’ portfolios.

Benzinga

Vertex Pharmaceuticals Clocks 27% Growth In Product Revenues, Issues FY22 Guidance

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) posted

1 … 4 5 6 7

People

Warren Buffett

1,292 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Vertex Pharmaceuticals

176 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.